DIAGNOSIS DAN TATA LAKSANA KEKAMBUHAN KUSTA

Authors

  • Caroline Oktarina Departemen Dermatologi dan Venereologi, Fakultas Kedokteran Universitas Indonesia/RSUPN dr. Cipto Mangunkusumo
  • Melani Marissa
  • Wresti Indriatmi
  • Sri Linuwih Menaldi

DOI:

https://doi.org/10.33820/mdvi.v49i2.340

Keywords:

kekambuhan, kusta, reaksi, resistensi, tata laksana

Abstract

Leprosy relapse is defined as the reappearance of leprosy’s signs and symptoms following completion of adequate Multidrug Therapy (MDT) regimen. Indonesia is the third biggest contributor for leprosy relapse with 284 cases in 2018. Several factors contribute to the occurrence of relapse, which include presence of persisters, history of inadequate therapy, drug resistance, history of irregular treatmenthistory of dapsone monotherapy, high initial bacteriological index, high number of skin and nerve lesions, negative lepromin test, history of antireaction therapy, human immunodeficiency virus (HIV) infection, and pregnancy. Diagnosis of relapse can be established based on clinical, bacteriological, and therapeutic criteria, also histopathological and serological criteria, if possible. With those criteria, it should be easier to differentiate relapse from reaction, resistance, reactivation, and reinfection. The principal management for leprosy relapse is re-administration of MDT according to the type of relapse; however, therapy should be modified if there are any evidences of drug resistance. Things which are important to be taken into account during relapse treatment are leprosy type, past medication history, and the possibility of drug resistance. With proper knowledge and diagnostic algorithm, it is expected that the treatment can be administered immediately in order to prevent disability and transmission of infection

Downloads

Download data is not yet available.

References

1. White C, Franco-Paredes C. Leprosy in the 21st century. Clin Microbiol Rev. 2015;28:80–94.
2. Global leprosy update, 2018: moving towards a leprosy-free world. 2019. Dalam: Weekly epidemiological record [Inter- net]. Geneva: World Health Organization; [389–412]. Diun- duh dari: https://www.who.int/wer/2019/wer9435_36/en/.
3. Thappa D, Kaimal S, Gupta D. Relapse in Leprosy. Dalam: Kumar B, Kar H, penyunting. IAL Textbook of Leprosy. Ed- isi ke-2. India: Jaypee Brothers Medical Publishers (P) Ltd.; 2017. h. 562–72.
4. Ferreira SMB, Ignotti E, Gamba MA. Fatores associados à recidiva em hanseníase em Mato Grosso. Revista de Saúde Pública. 2011;45:756–64.
5. da Silva Rocha A, Cunha M, Diniz LM, Salgado C, Aires MA, Nery JA, et al. Drug and multidrug resistance among Mycobacterium leprae isolates from Brazilian relapsed lep- rosy patients. J Clin Microbiol. 2012;50:1912–7.
6. Cardona-Castro N. Leprosy in Colombia. Curr Trop Med Rep. 2018;5:85–90.
7. Guerrero-Guerrero MI, Muvdi-Arenas S, Leon-Franco CI. Relapses in multibacillary leprosy patients: a retrospective cohort of 11 years in Colombia. Lepr Rev. 2012;83:247–60.
8. Sarkar R, Pradhan S. Leprosy and women. Int J Womens Der- matol. 2016;2:117–21.
9. Nogueira PSF, Moura ERF, Dias AA, Américo CF, Aguiar LR, Valente MMQP. Characteristics of pregnant and lactat- ing women with leprosy. Revista da Sociedade Brasileira de Medicina Tropical. 2015;48:96–8.
10. Ozturk Z, Tatliparmak A. Leprosy treatment during preg- nancy and breastfeeding: A case report and brief review of
11. 12.
13. 14.
15. 16.
17.
18. 19.
literature. Dermatol Ther. 2017;30.
Shen J, Yan L, Sun P. Clinical features of relapse after multi- drug therapy for leprosy in China. Lepr Rev. 2015;86:165–9. Teixeira LO, Silva CM, Akamatsu HT, Barreto JA, Soares CT. Neural relapse in multibacillary leprosy 6 years after end of treatment. An Bras Dermatol. 2012;87:305–8.
Gebre S, Saunderson P, Byass P. Relapses after fixed dura- tion multiple drug therapy: The AMFES cohort. Lepr Rev. 2000;71:325–31.
Saar M, Hanus I, Huber K, Beissner M, Loscher T, Bretzel G. Report on an unusual case of leprosy from Germany: just an exception of the rule? Infection. 2019;47:1065–9.
Naafs B, van Hees CL. Leprosy type 1 reaction (formerly re- versal reaction). Clin Dermatol. 2016;34:37–50.
Cambau E, Saunderson P, Matsuoka M, Cole ST, Kai M, Suf- fys P, et al. Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveil- lance network for the period 2009-15. Clin Microbiol Infect. 2018;24:1305–10.
Sales-Marques C, Cardoso CC, Alvarado-Arnez LE, Il- laramendi X, Sales AM, Hacker MA, et al. Genetic poly- morphisms of the IL6 and NOD2 genes are risk factors for inflammatory reactions in leprosy. PLoS Negl Trop Dis. 2017;11:e0005754.
Goncalves FG, Belone AFF, Rosa PS, Laporta GZ. Underly- ing mechanisms of leprosy recurrence in the Western Amazon: a retrospective cohort study. BMC Infect Dis. 2019;19:460. Gitte SV, Nigam C, Chakraborty AB, Kamble K, Soni M, Gahlot R. Profile of Person Affected by Leprosy with Clinical Relapse among in High Endemic State of India. J Microbiol Infect Dis. 2018:103–7.

Published

2023-02-20

How to Cite

Oktarina, C., Marissa, M., Indriatmi, W., & Menaldi, S. L. (2023). DIAGNOSIS DAN TATA LAKSANA KEKAMBUHAN KUSTA. Media Dermato-Venereologica Indonesiana, 49(2), 110–116. https://doi.org/10.33820/mdvi.v49i2.340